시장보고서
상품코드
1270837

세계의 NGS 기반 RNA 시퀀싱(RNA-Sep) 세계 시장 : 제품 및 서비스(샘플 준비, 플랫폼 및 소모품, 서비스, 데이터 분석), 기술(SBS, SMRT, 나노포어), 용도(de novo, 후성유전학, Small RNA), 최종 사용자 및 지역별 지역별 - 2027년까지 예측

NGS-based RNA-sequencing Market by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region - Global Forecast to 2027

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 202 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장 규모는 2022년 25억 달러에서 2027년까지 55억 달러에 달할 것으로 예상되며, 예측 기간 동안 17.2%의 CAGR을 나타낼 것으로 예상됩니다.

NGS를 통한 RNA 시퀀싱(RNA-Sep) 시장의 성장은 주로 기존 기술에 비해 RNA 시퀀싱의 장점, 게놈 시퀀싱 비용 감소, 유전체학 프로젝트를 지원하는 정부 자금 증가, RNA 시퀀싱을 포함한 연구 확대, 암 환자 증가, 암 연구에서 NGS 의 적용 확대, 개인 맞춤형 의료의 급격한 성장에 기인합니다. 반면, 유능한 전문가 부족, 신흥국의 최종 사용자의 예산 제약, 진단 테스트의 표준화 문제는 시장 성장을 제한할 것으로 예상됩니다.

"나노 모공 시퀀스 부문은 예측 기간 동안 상당한 CAGR로 성장할 것으로 예상됩니다."

기술별로는 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장은 SBS, 이온 반도체 시퀀싱, SMRT 시퀀싱, 나노포어 시퀀싱으로 구분됩니다. 나노포아 시퀀스 부문은 2022년부터 2027년까지 가장 높은 CAGR을 기록할 것으로 예상됩니다. 나노포아 시퀀싱은 직접적인 RNA 시퀀싱 기능을 가진 유일한 시퀀싱 기술입니다. 나노포아 시퀀싱은 다른 차세대 시퀀싱 기술에 비해 개별 뉴클레오타이드의 변형을 감지할 수 있는 네이티브 DNA 및 RNA의 단일 분자 시퀀스이기 때문에 프라이머가 16S 유전자의 전체 길이, 심지어 전체 리보솜 오퍼론까지 커버할 수 있다, 실시간 타겟 시퀀싱, 긴 리드 길이, 전체 길이의 cDNA 리드, 구조적 돌연변이의 확실한 검출 등의 장점으로 인해 최종 사용자들 사이에서 채택이 증가하고 있습니다.

"2021년, 용도별로는 발현 프로파일링 분석 부문이 시장을 장악할 것"

응용 프로그램별로 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장은 발현 프로파일링 분석, 소형 RNA 시퀀싱, de novo 전사체 어셈블리, 발암물질 전사체 후성유전학으로 구분됩니다. 기반 RNA 시퀀싱(RNA-Sep) 시장에서는 발현 프로파일링 분석 부문이 가장 큰 비중을 차지할 것으로 예상됩니다. 대사성 질환, 다발성 경화증 등의 유병률 증가는 발현 프로파일링 분석에 대한 수요를 촉진할 것으로 예상됩니다.

"2021년, 북미가 시장 점유율을 압도적으로 차지할 것"

NGS 기반 RNA 시퀀싱(RNA-Sep) 시장은 지역별로 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분되며, 2021년에는 북미가 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장의 주요 점유율을 차지할 것으로 예상됩니다. 북미는 정부 지원, RNA 시퀀싱 제품의 발전, 대상 질환의 유병률 증가, 암 및 유전성 희귀질환에 대한 연구 증가, 이 지역의 주요 기업의 강력한 존재감 등으로 인해 압도적인 점유율을 차지하고 있습니다. 그러나 아시아태평양 시장은 R&D에 대한 상당한 집중, NGS 제품 및 서비스 비용 감소, 주요 시장 참여자들이 아시아태평양에서 입지를 강화하는 데 주력하고 있기 때문에 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제

제6장 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장 : 제품 및 서비스별

  • 서론
  • RNA 시퀀싱(RNA-Sep) 플랫폼 및 소모품
  • 샘플 조제 제품
  • RNA 시퀀싱(RNA-Sep) 서비스
  • 데이터 분석 스토리지 및 관리

제7장 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장 : 기술별

  • 서론
  • SBS
  • 이온 반도체 시퀀싱
  • SMRT 시퀀싱
  • 나노포어 시퀀싱

제8장 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장 : 용도별

  • 서론
  • 발현 프로파일링 분석
  • Small RNA 시퀀싱(RNA-Sep)
  • DE NOVO TRANSCRIPTOME ASSEMBLY
  • VARIANT CALLING & TRANSCRIPTOME EPIGENETICS

제9장 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장 : 최종사용자별

  • 서론
  • 연구 및 학술
  • 병원 및 클리닉
  • 제약 기업 및 바이오테크놀러지 기업
  • 기타

제10장 NGS 기반 RNA 시퀀싱(RNA-Sep) 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카

제11장 경쟁 구도

  • 개요
  • 주요 기업 전략/유력 기업
  • 시장 점유율 분석
  • 시장의 주요 기업의 매출 점유율 분석
  • 경쟁 리더십 매핑
  • 경쟁 시나리오

제12장 기업 개요

  • 주요 기업
    • ILLUMINA, INC.
    • QIAGEN N.V.
    • PERKINELMER, INC.
    • EUROFINS SCIENTIFIC
    • OXFORD NANOPORE TECHNOLOGIES
    • AGILENT TECHNOLOGIES, INC.
    • BGI GROUP
    • GENEWIZ(PART OF BROOKS AUTOMATION)
    • HAMILTON COMPANY
    • NUGEN TECHNOLOGIES(PART OF TECAN TRADING AG)
    • PSOMAGEN(FORMERLY KNOWN AS MACROGEN)
    • F. HOFFMANN-LA ROCHE AG
    • THERMO FISHER SCIENTIFIC, INC.
    • TAKARA BIO, INC.
    • PACIFIC BIOSCIENCES
  • 기타 기업
    • ZYMO RESEARCH
    • LUCIGEN CORPORATION
    • GENOTYPIC TECHNOLOGY
    • OXFORD GENE TECHNOLOGY(PART OF SYSMEX)
    • BECTON, DICKINSON AND COMPANY

제13장 부록

LSH 23.05.24

The global NGS-based RNA-sequencing market is projected to reach USD 5.5 billion by 2027 from USD 2.5 billion in 2022, at a CAGR of 17.2% during the forecast period. Growth in the NGS-based RNA-sequencing market is mainly driven by the advantages of RNA sequencing over conventional technologies, the decreasing cost of genome sequencing, increasing government funding to support genomics projects, growing research involving RNA sequencing, growing cancer cases, the increasing application of NGS in cancer research, and rapid growth in personalized medicine. On the other hand, a lack of qualified specialists, end-user budget constraints in developing countries, and standardization concerns in diagnostic testing are expected to limit the market growth.

"Nanopore sequencing segment is anticipated to grow at substantial CAGR during the forecast period."

Based on technology, the NGS-based RNA-sequencing market has been segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. The nanopore sequencing segment is projected to register the highest CAGR from 2022 to 2027. Nanopore sequencing is the only sequencing technology with direct RNA-sequencing capabilities. The adoption of nanopore sequencing is increasing among end users due to its benefits as compared to other next-generation sequencing technologies, such as single-molecule sequencing of native DNA and RNA capable of detecting modifications in individual nucleotides allowing primers to cover the whole length of the 16S gene or even whole ribosomal operons, real-time targeted sequencing, large read lengths and full-length cDNA read, and reliable detection of structural variants.

"Expression profiling analysis applications segment dominated the market in 2021."

On the basis of application, the NGS-based RNA-sequencing market is segmented into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. In 2021, the expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing market. The increasing prevalence of metabolic disorders, multiple sclerosis, and other diseases are expected to propel the demand for expression profiling analysis.

"North America held the dominant share of the market in 2021."

Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the NGS-based RNA-sequencing market. North America held the dominant share owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 45%, Tier 2: 34%, Tier 3: 21%
  • By Designation - C-level: 47.0%, D-level: 33.0%, and Others: 20.0%
  • By Region - North America: 35%, Europe: 32%, Asia Pacific: 25%, Latin America: 6%, and the Middle East & Africa: 2%

List of Companies Profiled in the Report

    • Illumina, Inc. (US)
    • Thermo Fisher Scientific, Inc. (US)
    • PerkinElmer, Inc. (US)
    • QIAGEN N.V. (Netherlands)
    • Eurofins Scientific (UK)
    • Oxford Nanopore Technologies (UK)
    • Agilent Technologies, Inc. (US)
    • BGI Group (China)
    • GENEWIZ (US)
    • Hamilton Company (US)
    • NuGEN Technologies (US)
    • Psomagen, Inc. (South Korea)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Takara Bio, Inc. (Japan)
    • Pacific Biosciences (US)
    • Zymo Research Corporation (US)
    • Lucigen Corporation (US)
    • Genotypic Technology (India)
    • Oxford Gene Technology (UK)
    • Becton, Dickinson and Company (US)

Research Coverage:

This report provides a detailed picture of the global NGS-based RNA-sequencing market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total NGS-based RNA-sequencing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on NGS-based RNA-sequencing offered by the top 20 players in the NGS-based RNA-sequencing market. The report analyses the NGS-based RNA-sequencing market by product & service, technology, application, end user, and region.
  • Market Development: Comprehensive information about beneficial emerging markets. The report analyzes the markets for various NGS-based RNA-sequencing products and services across key geographic regions.
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-sequencing market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the NGS-based RNA-sequencing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
    • FIGURE 2 BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • FIGURE 4 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 APPLICATION-BASED MARKET ESTIMATION
    • FIGURE 5 APPLICATION-BASED MARKET ESTIMATION
  • 2.3 PRIMARY RESEARCH VALIDATION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
    • FIGURE 7 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 REGIONAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET

4 PREMIUM INSIGHTS

  • 4.1 NGS-BASED RNA-SEQUENCING MARKET OVERVIEW
    • FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER AND COUNTRY (2021)
    • FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
    • FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
    • FIGURE 16 NORTH AMERICA TO DOMINATE NGS-BASED RNA-SEQUENCING MARKET IN 2027

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Decreasing costs of genome sequencing
    • FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001-2021
      • 5.2.1.2 Advantages of RNA-sequencing over conventional technologies
      • 5.2.1.3 Increasing government funding to support genomics projects
      • 5.2.1.4 Growing research involving RNA-sequencing
      • 5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research
    • TABLE 1 CANCER INCIDENCE, 2020 VS. 2040
      • 5.2.1.6 Rapid growth in personalized medicine adoption
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of qualified specialists
      • 5.2.2.2 End-user budget constraints in developing countries
      • 5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Adoption of blockchain technology and cloud computing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Storage and interpretation of sequencing data
      • 5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts
      • 5.2.4.3 Ethical issues and challenges in testing procedure

6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 2 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES
    • 6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH
    • TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 SAMPLE PREPARATION PRODUCTS
    • 6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW
    • TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW
      • 6.3.2.1 Library preparation & target enrichment
      • 6.3.2.2 Quality control
    • 6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD
      • 6.3.3.1 Manual sample preparation
      • 6.3.3.2 Microfluidic sample preparation
      • 6.3.3.3 Robotic liquid handling sample preparation
  • 6.4 RNA-SEQUENCING SERVICES
    • 6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND
    • TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 DATA ANALYSIS, STORAGE & MANAGEMENT
    • 6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET
    • TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 23 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 SEQUENCING BY SYNTHESIS
    • 7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME
    • TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 ION SEMICONDUCTOR SEQUENCING
    • 7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES
    • TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING
    • 7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS
    • TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 NANOPORE SEQUENCING
    • 7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES
    • TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 44 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 EXPRESSION PROFILING ANALYSIS
    • 8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET
    • TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 SMALL RNA-SEQUENCING
    • 8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET
    • TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 DE NOVO TRANSCRIPTOME ASSEMBLY
    • 8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT
    • TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS
    • 8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT
    • TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 65 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 RESEARCH & ACADEMIA
    • 9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET
    • TABLE 66 NGS-BASED RNA-SEQUENCING MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 HOSPITALS & CLINICS
    • 9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET
    • TABLE 67 NGS-BASED RNA-SEQUENCING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET
    • TABLE 68 NGS-BASED RNA-SEQUENCING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 69 NGS-BASED RNA-SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 70 NGS-BASED RNA-SEQUENCING MARKET, BY REGION, 2020-2027(USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
    • TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 72 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 73 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 74 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Favorable funding scenario and growing R&D activity to drive market
    • TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 77 US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 78 US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Government initiatives for genome research to boost market
    • TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 80 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 81 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.3 EUROPE
    • TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 83 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 84 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 85 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 86 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany to dominate European market during forecast period
    • TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 88 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 89 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market
    • TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 91 UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 92 UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth
    • TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 94 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 95 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.4 REST OF EUROPE
    • TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 97 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 98 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
    • TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 100 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 101 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 102 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 103 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Established players and favorable government initiatives to drive market
    • TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 105 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 106 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market
    • TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 108 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 109 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Rising interest of companies for collaborations to drive market
    • TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 111 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 112 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 114 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 115 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 117 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 118 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 119 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 120 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 High HIV prevalence to drive demand for NGS in research
    • TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 122 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 123 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Economic growth and support for infrastructural development to propel market
    • TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 125 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 126 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 128 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 129 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET
    • TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 131 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 132 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 133 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING MARKET, 2019-2022
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 22 NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 134 NGS-BASED RNA-SEQUENCING MARKET: DEGREE OF COMPETITION
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 11.5 COMPETITIVE LEADERSHIP MAPPING
    • 11.5.1 TERMINOLOGY/NOMENCLATURE
      • 11.5.1.1 Visionary leaders
      • 11.5.1.2 Innovators
      • 11.5.1.3 Dynamic differentiators
      • 11.5.1.4 Emerging companies
    • FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET)
    • FIGURE 25 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS)
  • 11.6 COMPETITIVE SCENARIO
    • TABLE 135 NGS-BASED RNA-SEQUENCING MARKET: PRODUCT/SERVICE LAUNCHES
    • TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS
    • TABLE 137 NGS-BASED RNA-SEQUENCING MARKET: OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 12.1 KEY PLAYERS
    • 12.1.1 ILLUMINA, INC.
    • TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES
    • TABLE 140 ILLUMINA, INC.: DEALS
    • TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS
    • 12.1.2 QIAGEN N.V.
    • TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW
    • FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021
    • TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS
    • TABLE 144 QIAGEN N.V.: DEALS
    • 12.1.3 PERKINELMER, INC.
    • TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW
    • FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES
    • 12.1.4 EUROFINS SCIENTIFIC
    • TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021
    • TABLE 148 EUROFINS SCIENTIFIC: DEALS
    • 12.1.5 OXFORD NANOPORE TECHNOLOGIES
    • TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
    • TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES
    • TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS
    • TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS
    • 12.1.6 AGILENT TECHNOLOGIES, INC.
    • TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021
    • 12.1.7 BGI GROUP
    • TABLE 154 BGI GROUP: COMPANY OVERVIEW
    • TABLE 155 BGI GROUP: DEALS
    • 12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION)
    • TABLE 156 GENEWIZ: COMPANY OVERVIEW
    • TABLE 157 GENEWIZ: SERVICES LAUNCHED
    • 12.1.9 HAMILTON COMPANY
    • TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW
    • 12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG)
    • TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW
    • 12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN)
    • TABLE 160 PSOMAGEN: COMPANY OVERVIEW
    • 12.1.12 F. HOFFMANN-LA ROCHE AG
    • TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
    • FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021
    • TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS
    • 12.1.13 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
    • FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS
    • 12.1.14 TAKARA BIO, INC.
    • TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW
    • FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021
    • 12.1.15 PACIFIC BIOSCIENCES
    • TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
    • FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021
  • 12.2 OTHER PLAYERS
    • 12.2.1 ZYMO RESEARCH
    • 12.2.2 LUCIGEN CORPORATION
    • 12.2.3 GENOTYPIC TECHNOLOGY
    • 12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX)
    • 12.2.5 BECTON, DICKINSON AND COMPANY
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제